Cargando…

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

BACKGROUND: Overexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target. We report the first-in-human phase I study of BI 853520, a novel, potent, highly selective FAK inhibitor. OBJECTIVE: Our objectives were to identify the maxim...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407740/ https://www.ncbi.nlm.nih.gov/pubmed/30756308 http://dx.doi.org/10.1007/s11523-018-00617-1

Ejemplares similares

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
por: Verheijen, Remy B., et al.
Publicado: (2019)

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy
por: Keith, Bruce D
Publicado: (2008)

Metastases to the Breast from Extramammary Nonhematological Malignancies: Case Series
por: Wan, Xue, et al.
Publicado: (2020)

Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
por: Hirt, Ulrich A., et al.
Publicado: (2018)

Spectrum of nonhematological pediatric tumors: A clinicopathologic study of 385 cases
por: Punia, Rajpal Singh, et al.
Publicado: (2014)

The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
por: Tiede, Stefanie, et al.
Publicado: (2018)

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
por: Diaz-Padilla, Ivan, et al.
Publicado: (2013)

Hyperuricemic Renal Failure in Nonhematologic Solid Tumors: A Case Report and Review of the Literature
por: Saini, Neeraj, et al.
Publicado: (2012)

Metabolic toxicities in patients undergoing treatment for nonhematological malignancy: A cross-sectional study
por: Gupta, Subhash, et al.
Publicado: (2016)

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018)

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
por: Richter, Suzanne, et al.
Publicado: (2013)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: A clinical study of 19 cases
por: Ozkalemkas, Fahir, et al.
Publicado: (2005)

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
por: Shimizu, Toshio, et al.
Publicado: (2021)

Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer
por: Li, Hong, et al.
Publicado: (2021)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
por: Shimizu, Toshio, et al.
Publicado: (2022)

The mutational footprints of cancer therapies
por: Pich, Oriol, et al.
Publicado: (2019)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancer
por: Henderson, Matthew P.A., et al.
Publicado: (2016)

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
por: Chen, E X, et al.
Publicado: (2014)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
por: Razak, A R A, et al.
Publicado: (2011)

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)
por: Chiu, Joanne W., et al.
Publicado: (2015)

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma
por: Hirte, Hal W
Publicado: (2013)

Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options
por: Elit, Laurie, et al.
Publicado: (2013)

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
por: Voon, Pei Jye, et al.
Publicado: (2022)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
por: Janssen, Julie M., et al.
Publicado: (2022)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
por: Jiao, Wei, et al.
Publicado: (2020)

Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns
por: Jiao, Wei, et al.
Publicado: (2022)

Arousal and Consciousness in Focal Seizures
por: Blumenfeld, Hal
Publicado: (2021)

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material
por: de Leng, Wendy W. J., et al.
Publicado: (2016)

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy
por: Araujo, Daniel V, et al.
Publicado: (2021)

A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
por: Janse van Rensburg, Helena J., et al.
Publicado: (2023)

Run 43, 31.3.1971, 19.00-20.30, 15 GeV/c, 20 bunches: Q-jump, Stacking at the bottom with smaller buckets
por: De Jonge, M J, et al.
Publicado: (1971)

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
por: Iafolla, Marco A J, et al.
Publicado: (2020)

Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
por: Music, Milena, et al.
Publicado: (2020)

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer
por: Pezo, Rossanna C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4dathfrduvs8o2tv8kefcbra0q